# Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

> **NCT02287129** · PHASE2 · COMPLETED · sponsor: **Technical University of Munich** · enrollment: 75 (actual)

## Conditions studied

- Adenocarcinoma of the Esophagogastric Junction

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Epirubicin
- **DRUG:** Capecitabine
- **DRUG:** 5-FU
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** radiation
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT02287129
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-05
- **Primary completion:** 2020-08-07
- **Final completion:** 2020-08-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287129, "Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02287129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*